288 related articles for article (PubMed ID: 9815951)
1. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.
Dowsett M; Jones A; Johnston SR; Jacobs S; Trunet P; Smith IE
Clin Cancer Res; 1995 Dec; 1(12):1511-5. PubMed ID: 9815951
[TBL] [Abstract][Full Text] [Related]
2. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer.
Dowsett M; Pfister C; Johnston SR; Miles DW; Houston SJ; Verbeek JA; Gundacker H; Sioufi A; Smith IE
Clin Cancer Res; 1999 Sep; 5(9):2338-43. PubMed ID: 10499602
[TBL] [Abstract][Full Text] [Related]
3. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study.
Geisler J; Haynes B; Anker G; Dowsett M; Lønning PE
J Clin Oncol; 2002 Feb; 20(3):751-7. PubMed ID: 11821457
[TBL] [Abstract][Full Text] [Related]
4. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
[TBL] [Abstract][Full Text] [Related]
5. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
[TBL] [Abstract][Full Text] [Related]
6. Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.
Miller WR; Stuart M; Sahmoud T; Dixon JM
Br J Cancer; 2002 Oct; 87(9):950-5. PubMed ID: 12434282
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
[TBL] [Abstract][Full Text] [Related]
8. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer.
Dixon JM; Renshaw L; Young O; Murray J; Macaskill EJ; McHugh M; Folkerd E; Cameron DA; A'Hern RP; Dowsett M
J Clin Oncol; 2008 Apr; 26(10):1671-6. PubMed ID: 18375896
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women.
van der Wall E; Donker TH; de Frankrijker E; Nortier HW; Thijssen JH; Blankenstein MA
Cancer Res; 1993 Oct; 53(19):4563-6. PubMed ID: 8402628
[TBL] [Abstract][Full Text] [Related]
10. Endogenous aromatization of testosterone results in growth stimulation of the human MCF-7 breast cancer cell line.
Sonne-Hansen K; Lykkesfeldt AE
J Steroid Biochem Mol Biol; 2005 Jan; 93(1):25-34. PubMed ID: 15748829
[TBL] [Abstract][Full Text] [Related]
11. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention.
Harper-Wynne C; Ross G; Sacks N; Salter J; Nasiri N; Iqbal J; A'Hern R; Dowsett M
Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):614-21. PubMed ID: 12101108
[TBL] [Abstract][Full Text] [Related]
12. Refining the postmenopausal breast cancer treatment paradigm: the FACE trial.
Monnier A
Expert Rev Anticancer Ther; 2006 Oct; 6(10):1355-9. PubMed ID: 17069521
[TBL] [Abstract][Full Text] [Related]
13. Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.
Reed MJ; Lai LC; Owen AM; Singh A; Coldham NG; Purohit A; Ghilchik MW; Shaikh NA; James VH
Cancer Res; 1990 Jan; 50(1):193-6. PubMed ID: 2293555
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer.
Iveson TJ; Smith IE; Ahern J; Smithers DA; Trunet PF; Dowsett M
Cancer Res; 1993 Jan; 53(2):266-70. PubMed ID: 8417819
[TBL] [Abstract][Full Text] [Related]
15. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
Bottini A; Generali D; Brizzi MP; Fox SB; Bersiga A; Bonardi S; Allevi G; Aguggini S; Bodini G; Milani M; Dionisio R; Bernardi C; Montruccoli A; Bruzzi P; Harris AL; Dogliotti L; Berruti A
J Clin Oncol; 2006 Aug; 24(22):3623-8. PubMed ID: 16877730
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole.
de Jong PC; van de Ven J; Nortier HW; Maitimu-Smeele I; Donker TH; Thijssen JH; Slee PH; Blankenstein RA
Cancer Res; 1997 Jun; 57(11):2109-11. PubMed ID: 9187104
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
Mouridsen H; Chaudri-Ross HA
Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
[TBL] [Abstract][Full Text] [Related]
18. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.
Goss P; Bondarenko IN; Manikhas GN; Pendergrass KB; Miller WH; Langecker P; Blanchett D
J Clin Oncol; 2007 Nov; 25(31):4961-6. PubMed ID: 17971594
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
20. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
Kaufmann M; Rody A
Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
